This is the authors' abstract. We don't add key points for this paper.
Immunotherapy has emerged as a powerful strategy for combating cancer by harnessing the patient’s immune system to recognize and eliminate malignant cells. Major histocompatibility complex class I (MHC-I) plays a pivotal role by presenting neoantigens to CD8+ T cells, triggering T cell-mediated killing. However, cancer cells often evade detection by downregulating the MHC-I surface expression, hindering the immune response. This resistance mechanism offers an opportunity to bolster MHC-I surface expression via therapeutic interventions. We conducted a comprehensive evaluation of previously purported small molecule MHC-I inducers and identified heat shock protein 90 inhibitors as privileged enhancers. Using a core scaffold, we employed an in situ click chemistry-based derivatization strategy to generate 380 novel compounds. New agents showed high induction levels, with one triazole-based analogue, CliMB-325, also enhancing T cell activation and exhibiting lower toxicity. Altogether, we demonstrated the potential of click chemistry-based diversification for discovering small molecules to counter immune evasion.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Newkirk et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: